Metastatic Castration-Sensitive Prostate Cancer
Conditions
Interventions
Experimental arm: AZD5305 + Physician's Choice NHA (Abiraterone, Darolutamide, or Enzalutamide)
-Drug: AZD5305, Abiraterone Acetate, Darolutamide, Enzalutamide
Placebo Comparator arm: Placebo + Physic
Sponsors
Hibi Kazushige
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Male 18 years of age or more - Histologically documented prostate adenocarcinoma which is de novo or recurrent and castration-sensitive. Participants with pathologic features of small cell, neuroendocrine, sarcomatoid, spindle cell, or signet cell histology are not eligible. - Metastatic disease as documented by the investigator prior to randomisation, with clear evidence of 1 bone lesion or more and/or 1 soft tissue lesion or more that is suitable for repeated assessment with CT and/or MRI. - Participant is receiving ADT with a GnRH analogue or has undergone bilateral orchiectomy starting 14 days or more and < 4 months prior to randomisation - ECOG performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomisation. - Provision of FFPE tumour tissue sample and blood sample (for ctDNA) - Confirmed HRRm status by central tumour tissue and/or ctDNA test is required to determine cohort eligibility - Adequate organ and bone marrow function as described in study protocol - Participants must not father children or donate sperm from signing ICF, during the study intervention and for 6 months after the last dose of study intervention. - Participants must use a condom from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners.
Exclusion criteria
Exclusion criteria: - Participants with a history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). In case there is no clinical MDS/AML suspicion, no specific screening for MDS/AML (by BM/bone biopsy) is required. - Participants with any known predisposition to bleeding - Any history of persisting (> 2 weeks) severe cytopenia - Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305 and/or the assigned NHA. - History of another primary malignancy, with exceptions - Persistent toxicities (CTCAE Grade 2 or more) caused by previous anticancer therapy. - Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention - Cardiac criteria, including history of arrhythmia and cardiovascular disease - Any prior anticancer pharmacotherapy or surgery for metastatic prostate cancer, with exceptions: - Prior treatment within 14 days with blood product support or growth factor support. - Participants who are unevaluable for both bone and soft tissue progression
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radiographic Progression-Free Survival (rPFS) [ Time Frame: up to approximately 50 months ] rPFS is defined as the time from randomisation to radiographic progression, as assessed by the investigator per RECIST 1.1 (soft tissue) and/or PCWG3 criteria (bone), or, death due to any cause. | — |
Countries
Australia, Austria, Belgium, Brazil, Canada, Chile, China, Finland, France, Germany, Hungary, India, Italy, Japan, Malaysia, Netherlands, Peru, Poland, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, United States of America
Contacts
Public ContactKazushige Hibi
Astrazeneka K.K
Outcome results
None listed